Organization

Alector, Inc.

About

Alector is a biotechnology company that is using their insights into human genetics, immunology, and neuroscience to develop new therapeutic treatments for neurodegenerative disease. The company currently has an industry leading portfolio of immuno-neurology programs that are designed to equip and empower the brain's immune system to fight disease.

Overview

Founded 2013
Type Public
Location San Francisco, California, USA

Stock

ALEC $9.45 -0.42% $(0.04)

Latest News

Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD) Sep 12, 2022 GlobeNewswire Inc. AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD
Why Immunocore Shares Dipped 22%; Here Are 73 Biggest Movers From Friday Sep 12, 2022 Benzinga Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares climbed 71.9% to close at $2.20 on Friday after the company received a non-binding go-private proposal from...
Dow Climbs More Than 400 Points, S&P 500 Rises 1.5% Sep 09, 2022 Benzinga U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 400 points on Friday. The Dow traded up 1.34%...
Why Zscaler Is Trading Higher By Around 19%, Here Are 44 Stocks Moving In Friday's Mid-Day Session Sep 09, 2022 Benzinga Gainers Digital Media Solutions, Inc. (NYSE: DMS) shares jumped 70% to $2.1750 after the company received a non-binding go-private proposal from Prism Data for $2.50...
Morgan Stanley Downgrades Alector: Here's What You Need To Know Sep 09, 2022 Benzinga Morgan Stanley downgraded its rating of Alector (NASDAQ:ALEC) to Equal-Weight with a price target of $13.00, changing its price target from $27.00 to $13.00. Shares...